

Anna McGlothlin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6740239/publications.pdf>

Version: 2024-02-01

25
papers

4,990
citations

471509

17
h-index

610901

24
g-index

26
all docs

26
docs citations

26
times ranked

8103
citing authors

#	ARTICLE	IF	CITATIONS
1	Hypothermia for Patients Requiring Evacuation of Subdural Hematoma: A Multicenter Randomized Clinical Trial. <i>Neurocritical Care</i> , 2022, 36, 560-572.	2.4	7
2	Effect of P2Y12 Inhibitors on Survival Free of Organ Support Among Non-Critically Ill Hospitalized Patients With COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 2022, 327, 227.	7.4	89
3	Effect of Antiplatelet Therapy on Survival and Organ Support-Free Days in Critically Ill Patients With COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 2022, 327, 1247.	7.4	83
4	Optimizing Sample Size Allocation and Power in a Bayesian Two-Stage Drop-the-Losers Design. <i>American Statistician</i> , 2021, 75, 66-75.	1.6	1
5	Sutureless versus conventional bioprostheses for aortic valve replacement in severe symptomatic aortic valve stenosis. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2021, 161, 920-932.	0.8	55
6	Effect of Vitamin C, Thiamine, and Hydrocortisone on Ventilator- and Vasopressor-Free Days in Patients With Sepsis. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 742.	7.4	168
7	Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19. <i>New England Journal of Medicine</i> , 2021, 384, 1491-1502.	27.0	1,419
8	Practical Considerations and Recommendations for Master Protocol Framework: Basket, Umbrella and Platform Trials. <i>Therapeutic Innovation and Regulatory Science</i> , 2021, 55, 1145-1154.	1.6	31
9	Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial. <i>Intensive Care Medicine</i> , 2021, 47, 867-886.	8.2	65
10	Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19. <i>New England Journal of Medicine</i> , 2021, 385, 790-802.	27.0	778
11	Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19. <i>New England Journal of Medicine</i> , 2021, 385, 777-789.	27.0	712
12	Effect of Convalescent Plasma on Organ Support-Free Days in Critically Ill Patients With COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 1690.	7.4	169
13	The design of a Bayesian adaptive clinical trial of tranexamic acid in severely injured children. <i>Trials</i> , 2021, 22, 769.	1.6	6
14	Comparison of methods for control allocation in multiple arm studies using response adaptive randomization. <i>Clinical Trials</i> , 2020, 17, 52-60.	1.6	33
15	Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 1317.	7.4	671
16	Comparison of response adaptive randomization features in multiarm clinical trials with control. <i>Pharmaceutical Statistics</i> , 2020, 19, 602-612.	1.3	16
17	In response: Letter on update to the Vitamin C, Thiamine and Steroids in Sepsis (VICTAS) protocol. <i>Trials</i> , 2020, 21, 351.	1.6	1
18	The REMAP-CAP (Randomized Embedded Multifactorial Adaptive Platform for Community-acquired) Trial. <i>Journal of Intensive Care Medicine</i> , 2020, 35, 1075-1083.	8.2	245

#	ARTICLE	IF	CITATIONS
19	The Vitamin C, Thiamine and Steroids in Sepsis (VICTAS) Protocol: a prospective, multi-center, double-blind, adaptive sample size, randomized, placebo-controlled, clinical trial. <i>Trials</i> , 2019, 20, 197.	1.6	57
20	Update to the Vitamin C, Thiamine and Steroids in Sepsis (VICTAS) protocol: statistical analysis plan for a prospective, multicenter, double-blind, adaptive sample size, randomized, placebo-controlled, clinical trial. <i>Trials</i> , 2019, 20, 670.	1.6	7
21	Two Phase 1 dose-escalation studies exploring multiple regimens of lironesib (LY2523355), an Eg5 inhibitor, in patients with advanced cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 79, 315-326.	2.3	25
22	Interpretation of Clinical Trials That Stopped Early. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 1646.	7.4	29
23	Association of Pathologic Complete Response to Neoadjuvant Therapy in HER2-Positive Breast Cancer With Long-Term Outcomes. <i>JAMA Oncology</i> , 2016, 2, 751.	7.1	243
24	Binary Regression with Misclassified Response and Covariate Subject to Measurement Error: a Bayesian Approach. <i>Biometrical Journal</i> , 2008, 50, 123-134.	1.0	18
25	PET-CR as a potential surrogate endpoint in untreated DLBCL: meta-analysis and implications for clinical trial design. <i>Leukemia and Lymphoma</i> , 0, , 1-16.	1.3	1